Key Takeaways
- Demand recovery begins, but uneven: Domestic crop care delivered ~8% volume growth as monsoon and crop prices improved, while international revenue fell 5% despite 19% volume growth on persistent price pressure.
- Margin compression is structural and mix-driven: Gross margin fell because the higher-margin seeds business shrank 16% and both domestic and export crop protection margins are running below historical levels, not because exports turned loss-making.
- Portfolio cleanup is now an explicit strategy: Management will phase out low-margin, undifferentiated products and pursue a "make vs buy" approach, but this is a slow process, not a switch.
- Seeds is being managed for profit, not volume: A 16% revenue drop from supply shortages was paired with a 4% gross contribution improvement, reflecting a deliberate shift to avoid inventory write-off risk.
- What to watch next quarter: Whether the monsoon-driven domestic sentiment converts to liquidation, whether export price stabilization turns into actual recovery, and any quantification of the portfolio phase-out timeline.
Domestic Crop Protection: Volume Returns, Price Lags
- Volume-led growth of ~8% was driven by herbicides and recent launches like Clasto, with the herbicide portfolio growing faster on labor dynamics even though the company acknowledges a portfolio gap it is working to fill.
- Price declines persist in parts of the portfolio where the company competes directly without strong brand differentiation, forcing it to price at par with the market.
- Rabi inventory correction weighed on the quarter as high trade inventory from the poor rabi crop was cleared; management says the number is not sizable and the situation should only improve as monsoon progresses.
- Cotton acreage reduction in northern India from pink bollworm pressure is a headwind, but the company's Diggaz hybrid (shorter duration to beat the pest) moved from 2,00,000 to 4,00,000 packets and liquidation is believed to be very high.
- New product engine is turning: Five products launched in crop care during the quarter, and the ambition is for the Innovation Turnover Index to move into the high teens, with an uptick already visible in Q1.
Shukla: "I think it's always a combination of what product mix I have got and what others have got. So, we are aware of this fact, and I think our attempt is to start looking at portfolio and start cleaning up so that we are continuously improving our margins and that will only come from portfolio churn is a phase out process, it's not a start and stop switch."
International Business: Volume Strength, Price Pain
- Revenue fell 5% despite 19% volume growth, as prices for old technicals like Acephate, Hexaconazole and Pendimethalin remain muted; Metribuzine prices are at half of two years ago.
- Sea freight costs doubled (Baltic Dry Index) over the last year, adding margin pressure on top of price weakness.
- The business remained EBITDA-positive despite the drop; management explicitly stated it did not make a negative margin, though contribution levels are lower than last year and some specific deals carried very little margin because of held inventory.
- Price stabilization is starting sequentially: price drops have stopped worsening, and as the steep YoY declines begin to anniversarize, the growth optics should improve.
- Acephate remains the weakest link, facing continued challenges in Brazil and the US, while Pendimethalin operated at low capacity but management is more optimistic about its long-term prospects.
- New relationships with global majors for old technicals and expanding formulation alliances are underway to build a more resilient portfolio, but the near-term outlook remains challenging for at least three months.
Shukla: "I do not know either I am able to predict, there's no crystal ball in my hand to say what will happen."
Seeds: Profit Over Volume, Supply Chain Bites
- Revenue dropped 16% due to seed supply shortages in several crops, primarily hybrid maize and hybrid paddy, which are a significant part of revenue.
- Gross contribution improved 4% through prudent cost management and pricing, reflecting a deliberate philosophy shift to manage seeds for profit rather than volume, because unsold seed inventory becomes a write-off.
- Supply chain requires two years of planning: what the company wants to sell in 2025 needs production this year, with parent seed produced in 2023; two consecutive years of drought in southern India during the critical September-December window, followed by excess rain and water shortage, created competition for seed crop acres.
- Diggaz is the bright spot: the shorter-duration hybrid cotton launched in the North saw good volume growth on significantly lower cotton area planted; the key monitorable now is farmer yield experience after two pickings compared with other brands.
- Cotton seeds overall: management is hopeful this year will deliver the highest ever cotton packet volumes between North and Southwest, with North cotton expected to see significant growth over last year's actual liquidation; production packet constraints capped volumes further.
Shukla: "I think we are just trying to manage the whole business for profit rather than trying to say, we will just shape the volume in this because seed inventory can come to haunt us very badly. It all becomes a write-off."
Crop Nutrition: The Bright Spot
- Grew 31% in the quarter, continuing to be a strong pillar for long-term growth.
- A Water-Soluble Fertiliser Plant was commissioned during the year, adding capacity to a segment management finds attractive and relatively higher-margin.
- The segment is a stated investment priority alongside the herbicide portfolio build-out, as the company shapes its B2C future around crop protection, nutrition, and seeds managed for profitability.
Margin Walk & Cost Pressures
- Gross margin compression came from two sources: a negative mix shift because Q1 seeds (a larger proportion of the portfolio) saw its own margin come down, and both domestic and international crop protection margins are running relatively poorer than historical levels.
- Other expenses rose from ~₹125 crore to ~₹135 crore on a largely flat sales base, driven by an electoral trust contribution, higher freight costs, and investments behind digital initiatives including the SAP HANA migration.
- Digital investment will increase further, focused on customer-facing tools (Drishti for satellite-based farmer warnings, Anubandh for channel visibility) and manufacturing automation, though no forward run-rate or ROI metrics were provided.
- Portfolio cleanup is the margin recovery path: phasing out products that do not make money or are too small (bringing supply chain complexity) and replacing them with differentiated products where margins are relatively better, but this is a journey that takes time and does not show in a very short period for a seasonal business.
- Certain technical prices are creeping up MoM/QoQ; where brand strength exists to absorb increases it will be possible, but elsewhere it may lead to further margin compression.
Shukla: "I think we are moving to a mindset to say we have to make a smart decision, make versus buy, in a world where so many supply chain and product partnerships are available."
Strategic Reset: Partnerships, Portfolio & People
- A mindset shift from "do everything on our own" to being a more collaborative partner for global and domestic companies is underway; make-vs-buy decisions will be based on pure economic decision-making while ensuring certainty of supplies.
- Contract manufacturing alliances with global players are being expanded to build a more resilient portfolio, and management is confident this will meaningfully contribute to both top line and bottom line in the years to come.
- A new-age portfolio based on peptides, enzymes and biologicals is being invested in, which will eventually become the fourth segment from a customer perspective alongside crop protection, nutrition and seeds.
- An integrated R&D facility in Bangalore will bring two R&D capacities together at one center and should be ready in two years; in seeds, the attempt is to focus money on fewer things rather than spreading it thinly and to deploy modern breeding tools to reduce product development time from 8-10 years.
- Leadership changes are being evaluated to bring fresh thinking, and the organization is being looked at for rightsizing.
- CAPEX is envisaged at around ₹100 crore, with continued focus on improving capital efficiencies for both working and fixed capital.
Shukla: "Group is committed to this business and there's a lot of support, and I have been saying this is the only direct farmer facing business we have."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| International business outlook | Remains challenging | At least next three months |
| Export price recovery | Price drops stabilized sequentially; YoY declines to anniversarize, so steeper drops should not manifest | Implicitly H2 FY25 as base effects kick in |
| Portfolio phase-out | Phase out products that do not make money or are too small | No date; described as a "journey that takes time" |
| Digital investment | Investment to further go up; customer and manufacturing automation are focus areas | No date; ongoing |
| CAPEX | ~₹100 crore envisaged | No date |
| Integrated R&D facility | Two R&D capacities brought together at one center in Bangalore | Ready in two years |
| Innovation Turnover Index | Ambition to move to high teens; uptick already seen in Q1 | No date; directionally stated |
| Cotton seeds volume | Hopeful of highest ever cotton packets this year | FY25 |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Revenue | ₹783 cr, flat YoY vs ₹782 cr |
| Volume growth | 9% overall |
| EBITDA | ₹96 cr, down 13% YoY from ₹110 cr |
| Gross contribution margin | 30% |
| PAT | ₹48 cr, down from ₹63 cr in Q1 FY24 |
| Domestic Crop Care revenue growth | 13% YoY |
| Domestic Crop Care volume growth | 13% |
| Domestic Crop Care price decline | upwards of 10% YoY, 14% QoQ |
| Crop nutrition revenue growth | 31% |
| International business revenue | ₹133 cr, down 5% YoY |
| International business volume growth | 19% |
| Seeds revenue growth | -16% |
| Seeds EBITDA margin | 22%, up from 20% YoY |
| Seeds gross contribution improvement | 4% YoY |
| CAPEX guidance | ₹100 cr for the year |
| New products launched | 5 in crop care, 14 in seeds |
| Diggaz cotton seed packets | ~4,00,000 last year, up from 2,00,000 two years ago |
| Other expenses | ₹135 cr, up from ₹125 cr YoY |
| Kharif sowing growth | ~10% vs last year |
| Paddy sowing growth | 21% |
| Soyabean sowing growth | 30% |
| Maize sowing growth | 34% |
| Pigeon pea sowing growth | 191% |
| Baltic Dry Index | doubled over last year |
| Metribuzin price level | ~half of what it was two years ago |
| Crop nutrition share of domestic crop care | 10–15% |
| Seeds R&D spend | 8–10% of seeds sales in FY24 |
| EBITDA drop from seeds | ₹4 cr YoY |
| EBITDA drop from crop care (incl. international) | ₹10 cr YoY |